ImmunoGen Executives
ImmunoGen employs about 277 people. The company is managed by 14 executives with a total tenure of roughly 16 years, averaging almost 1.0 years of service per executive, having 19.79 employees per reported executive. Analysis of ImmunoGen's management performance can provide insight into the firm performance.
| Mark Enyedy CEO President CEO, Director |
| Theresa Wingrove President Vice President - Regulatory Affairs and Quality |
ImmunoGen |
ImmunoGen Management Team Effectiveness
The company has return on total asset (ROA) of (0.0849) % which means that it has lost $0.0849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1988) %, meaning that it created substantial loss on money invested by shareholders. ImmunoGen's management efficiency ratios could be used to measure how well ImmunoGen manages its routine affairs as well as how well it operates its assets and liabilities.ImmunoGen Workforce Comparison
ImmunoGen is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 3,306. ImmunoGen holds roughly 277 in number of employees claiming about 8% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.26) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.23 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.23. ImmunoGen Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ImmunoGen insiders, such as employees or executives, is commonly permitted as long as it does not rely on ImmunoGen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ImmunoGen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
White Lauren over a year ago Acquisition by White Lauren of 19519 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 27788 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 6792 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 166725 shares of ImmunoGen subject to Rule 16b-3 | ||
Richard Wallace over a year ago Exercise or conversion by Richard Wallace of 10000 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 158641 shares of ImmunoGen subject to Rule 16b-3 | ||
White Lauren over a year ago Acquisition by White Lauren of 295975 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Acquisition by Theresa Wingrove of 23400 shares of ImmunoGen subject to Rule 16b-3 |
ImmunoGen Notable Stakeholders
An ImmunoGen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ImmunoGen often face trade-offs trying to please all of them. ImmunoGen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ImmunoGen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Mark Enyedy | President CEO, Director | Profile | |
| Theresa Wingrove | Vice President - Regulatory Affairs and Quality | Profile | |
| Daniel JD | VP Officer | Profile | |
| Susan Altschuller | VP CFO | Profile | |
| MMSc MD | VP Officer | Profile | |
| Lauren MBA | Senior Officer | Profile | |
| Renee Lentini | VP Officer | Profile | |
| Stacy Coen | Sr Officer | Profile | |
| Audrey Bergan | Senior Officer | Profile | |
| Courtney OKonek | Senior Relations | Profile | |
| Isabel Kalofonos | Senior Officer | Profile | |
| Anabel Chan | Head Relations | Profile | |
| FACP MD | VP Affairs | Profile | |
| Stacy MBA | Senior Officer | Profile |
ImmunoGen Workforce Analysis
Traditionally, organizations such as ImmunoGen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ImmunoGen within its industry.ImmunoGen Manpower Efficiency
Return on ImmunoGen Manpower
| Revenue Per Employee | 1M | |
| Revenue Per Executive | 20.5M | |
| Net Loss Per Employee | 265.4K | |
| Net Loss Per Executive | 5.3M | |
| Working Capital Per Employee | 658K | |
| Working Capital Per Executive | 13M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |